You are here

Home » Content

PİROFOSFATVE BİSFOSFONATLARIN KALSİFİKASYON ÜZERİNE ETKİLERİ

THE EFFECTS OF PYROPHOSPHATES AND BISPHOSPHONATES ON CALCIFICATION

Journal Name:

  • İstanbul Üniversitesi Diş Hekimliği Fakültesi Dergisi

Publication Year:

  • 1996

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
This paper reviews the actions on calcification of the inorganic pyrophosphate and bisphosphonates. Pyrophosphate was found to occur in many biological fluids and inhibited the precipitation of calcium phosphates. It also slowed the transformation of amorphous calcium phosphate to its crystalline form, and inhibited crystal aggregation and dissolution. These results suggested that it might be a compound of physiological significance. Bisphoshonates are compounds where the P-O-P bond of pyophoshate is replaced by a P-C-P bond. These analogues have similar properties to pyrophosphate, but unlike pyrophosphate they are resistant to enzymic and chemical hydrolysis. Bishosphonates bind to hydroxyapaiite cystals and in vitro inhibit both crystal formation and dissolution. In vivo, they inhibit soft tissue calcification and normal calcification. Furthermore they are very potent inhibitors of bone resoption. Bisphosphonates accumulated specifically in mineralized tissues. The mechanisms of action for the inhibition of calcification is probably involves an inhibition of calcium phosphate crystal growth. However the mode of action on bone resorption is more likely to be cellular. Bisphosphonates have been used in man to prevent heterotopic calcification, dental calculus, and dental caries and to slow down bone resorption in conditions such as postmenopausal osteoporosis, Paget's disease and osteoporotic immobilisation.
Bookmark/Search this post with
Abstract (Original Language): 
inorganik pirofosfat ye bisfosfonatların kalsifikasyon üzerine etkileri incelenmiştir. Pirofosfat biyolojik sıvılarda bulunur ve kalsiyum fosfatın çökelmesini engeller. Aynı zamanda amorf kalsiyum fosfatın kristal haline dönüşmesini yavaşlatır ve kristal kümelenmesi ve çözülmesini inhibe eder. Bu sonuçlar pirofosfatm fizyolojik öneme sahip bir bileşik olabileceğini gösterir. Bisfosfonatlar pirofosfattaki POP yerine P-CP bağları içeren bileşiklerdir. Bu maddelerin Özellikleri pi-rofosfatınkilere benzer. Fakat pirofosfatm aksine kimyasal ve enzimatik hidrolize dirençlidir. Hidroksia-patit kristallerine bağlanır ve in vitro hem kristal oluşmasını hem de kristal çözülmesini inhibe eder. İn vivo yumuşak doku kalsifikasyonlarım ve normal kalsifi-kasyonu önler. Bu maddeler ayın zamanda kemik re-zorpsiyonunun güçlü inhibitörleridir. Bisf osf onatlar özellikle sert dokularda birikir. Kalsifikasyonun inhi-. bisyonuna ilişkin etki mekanizması kalsiyum fosfat kristallerinin büyümesinin engellenmesidir. Ancak kemik rezorpsiyonu üzerine etkisi büyük bir olasılıkla hücresel olabilir. Bisfosfonaüar insanlarda heterotopik kalsifikasyon, diştaşi oluşumu ve diş çürüklerinin önlenmesinde, Paget hastalığı, ,osteoporotikimmobilizasyon ve postme-nopozal osteoporozis gibi hastalıklarda kemik rezorp-siyonunu yavaşlatmak için kullanılmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-pirofosfatve-bisfosfonatlarin-kalsifikasyon-uzerine-etkileri.pdf
  • 2
105
111
  • Turkish

REFERENCES

References: 

1. Adachi H, Igarashi K, Mitani H, Shinoda H. Effects of topical administration of a bisphosphonate (Risedronate) on orthodontic tooth movements in rats. JOent Res 1994; 73: 1478-84.
2. Anbar M, St John GA, Elward TE. Organic polymeric polyphosphonates as potential preventive agents of dental caries: In vivo experiments./!)™* flesl974;55: 1240-4.
. 3. Anbar M, St John GA, Scott AC. Organic polymeric polyphosphonates as potential preventive agents of dental caries: In vitro experiments. J Dent Res 1974; 55:867-8.
4. Bassett GAL, Donath A, Macagno F, Preisig R , Fleisch H. Diphosphonates in the treament of myositis ossificans. Lancet 1969; 2:845.
5. Bauer FCH, Nilsson OS, Tornkvist H, Undholm TC, Lindholm TS. Effect of diphosphonate on the osteoinductive activity of rat bone matrix. Clin Orthop Rel Res 1984; 185: 266-9.
6. Bisaz S, Felix R, Hansen NB, Fleisch H Disaggregation of hydroxyapatite crystals. Biochim Biophys Acta 1976; 451: 560-6.
7. Bisaz S, Russell RGG, Fleisch H. Isolation of inorganic pyrophasphate from bovine and human teeth. Arch OralBi-oi 1968; 13: 683-96.
8. Bisaz S, Schenk R, Kunin AS, Russcl RGG, MCihlbauer R, Fleisch H. The comparative effects of vitamin D deficiency and ethane- 1-hydroxy-l, 1-diphosphonate administration on the histology and glycolysis of chick epiphyseal and articular cartilage. Calc Tiss Res 1975; 19:139-52.
9. Bloom W, Fawcett WD. The mechanism of calcification. In: A Textbook of Histology. 2nd cd. Philadelphia: W B Saunders Comp, 1972; 269-72,
10 Boskey AL, Goldberg MR, Posner AS. Effect of diphosphonates on hydroxyapatite formation induced by calci-um-phospholipid-phosphate complexes. Calc Tiss Intl 1979; 27: 83-8.
11. Briner WW, Francis MD, Widder JS. The control of dental calculus in experimental animals. IntDentJ 1971; 21: 61-73.
12. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.J Clin Invest: 1990; 85: 456-61,
13. Cecchini MG, Felix R, Fleisch H, Cooper PH. Effect of bisphosphonates on proliferation oand viability of mouse bone marrow-derived macrophages JBoneMin Res 1987; 2: 135-42.
14. Chambers TJ. Diphosphonates inhibit bone resorption by macrophages in vitroj Patlwlogy 1980; 132:255-62.
15. Chapuy MC, Briancon D, Vignon E, Durhon S, Meu-nier PJ. The short-term effects of intravenous EHDP in Pa-get's disease of bone. Calc Tiss Intl 1982;5^:29.
16. Cram RL, Barmada R, Ray RD. Diphosphonate treament
of calcinosis universalis, NEnglJ Med 1972; 285:1012¬3,
17. Doty SB,Jones R, Finerman GA. Diphosphonate influence on bone cell structure and lysosomal activity. J Bone faint Surg 1972; 54A: 1128-9.
18. Evans JR, Robertson WG, Morgan DB, Fleisch H. Effects of pyrophosphate and diphosphonates on the dissolution of hydroxyapatites using a flow system. Calc Tiss Intl 1980; 31:153-9.
19. Felix R, Russell RGG, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Ada 1976; 429: 429-38.
20. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bishosphonates: Interactions between bisphosphonates, osteoclasts and bone. CalcifTiss Int 1991; 49: 407-15.
21. Fleisch H. Experimental basis for the use of bisphosphonates in Paget's disease of bone. C/tn Orthop Rel Res 1987; 217: 72-8.
22. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Amer J Physiol 1962; 203: 671-5.
23. Fleisch H, Bisaz, S. Mechanism of calcification: Inhibitory role of pyrophosphate. Nature 1962; 195:911.
24. Fleisch H, Bisaz S. The inhibitory effect of pyrophosphate on calcium oxalate precipitation and its relation to urolithiasis. Experientia 1974; 20: 276-7.
25. Fleisch H, MaerkiJ, Russell RGG. Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol Med 1966; 122:317-20.
26. Fleisch H, Russell RGG. Experimental and clinical studies widi pyrophosphate and diphosphonates. In: Davids S, David eds. Calcium Metobolism in Renal Failure and Nephrolithiasis. John Wiley and Sons. Inc. 1977; 293-336.
27. Fleisch H, Russell RGG, Bisaz S, Miıhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney deification in vivo, Europ J Gin Invest 1970; 1: 12-8.
28. Fleisch H, Russell RGG, Simpson B, Miihlbauer RC. Prevention by a diphosphonate of immobilization "osteoporosis" in rats. Nature 1969; 223:211-2.
29. Francis MD, Briner WW: The effect of phosphonates on dental enamel in vitro and calculus formation in vivo. CalcTiss Res 1973; 11: 1-9.
30. Francis MD, Flora L, King WR. The effects of disodi-um ethane-l-hydroxy-1, 1-disphosphonate on adjuvant-induced arthritis in rats. Calc Tiss Res 1972;109-21.
31. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological clacification in vivo. Science 1969; 165:
110
İnce S
1264-6.
32. Francis MD, Slough GL, Briner WW, Oertel RP. An in vitro and in vivo investigation of mellitate and ethane-l-hydroxy-1, 1-diphosphonate in calcium phosphate systems. Calc Tiss Res 1977; 23: 53-60.
33. Fraser D, Russell RGG, Pohler O, Robertson WG, Flefsch H. The influence of disodium ethane-l-hydroxy-1,1-diphosphonate (EHDP) on the development of experimentally induced urinary stones in rats. Qa Sei 1972; 42:197¬207.
34. Geusens P, De Vos P, DequekerJ. 24-hour Techneti-um-99m-methylene diphosphonate-re tendon in metabolic bone disease, with special reference to symptomatic idiopathic postenopausel osteoporosis. Cale Tiss Inti 1981; S33: 138.
35. Glimcher MJ, Krane SM. The oganization and structure of bone and mechanism of calcification. In; Ramac-handran GN, Gould BS ed. Treatise on collagen. IIB Biology of Collagen. Academic Press, 1968.
36. Guilland DF, SallisJD, Fleisch H. The effect of two diphosphonates on the hadling of calcium by rat kidney mitochondria in vitro. Cale Tiss Res 1974; 15: 303-14.
37. Hansen NB, Felix R, Bisaz S, Fleisch H. Aggregation of hydroxyapatite crystals. Biochim BiophsyActa 1976; 451: 549-59.
38. Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahling-haus-Nienhuys PJ. Efficacious management with amino-bisphosphonate (APD) in Paget's disease of bone. CKn Orthop Rel Res 1987; 217:79-84.
39. Hughes DE, Mac Donald BR, Russel RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J din Invest 1989; 55:1930-5.
40. Igarashi K, Mitani H, Adachi H ve Shinoda H. Anchorage and retentive effects of a bisphosphonate on tooht movenments in rats. Am JOrihod Dentofac Orthop 1994; 106: 279-89.
41. Ikeo T, Takaya T.Yamauchi K, Miwa M, Shioji I, Saki-yama Y. Effect of ethane-l-hydroxy-1, 1-diphosphonate (EHDP) on fetal mice during pregnancy. / Osaka Univ 1987; 21: 45-53.
42. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Cale Tiss Res 1973; 11:269-80.
43. King WR, Francis MD, Michael WR. Effect of disodium ethane-l-hydroxy-1,1-diphosphonate on bone formation. Clin Orthop 1971; 78: 251-70.
44. Koch G, Bergmann-Ardodottir I, Bjamason S, Finn-bogason S, Höskuldsson O, Karlsson R. Caries-preventive effect of fluoride dentrifrices with and without anticakulus agents: A 3-year controlled clinical trial Caries Res 1990; 24: 72-9.
45. Larsson A. The short-term effects of high doses of ethylene-l-hydroxy-1, 1-diphosphonate upon early dentin formation. Gate Tiss Res 1974; 16:109-27.
46. Larrson A, Larsson SE. Studies on dentinogenesis in the rat. Ethane-l-hydroxy-1,1-diphosphonate (EHDP) inhibits crystal growth in predentin calcification. Wtrchows Arch Abt A Path Anatl 973; 360:315-25,
47. Leonard EP, Reese WV, Mandel EJ. Comparison of the effect of ethane-l-hydroxy-1, 1-diphosphonate and dichloromethylene diphosphonate upon periodontal bone resorption in rice rats. Arch Oral Biol 1979; 24: 707-8.
48. Mazess RB; Bendsen H, Dawros W. 99m Tc-diphosp-honate retention by whole-body profile scanning. CalcTiss Intl 1982; S34: 34.
49. Meyer JL, Lee KE, BargcrtJH. The inhibition of caelum oxalate crystal growth by multidentate organic phosphonates. Effect ofpH Calc Tiss Res 1977; 28: 83-6.
50. Meyer JL, Nancollas GH. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calc Tiss Res 1973; 13: 295-303.
51. Michael WR, King WR, WakimJM. Metabolism of disodium ethane-l-hydroxy-1, 1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972; 21: 503-15.
52. Miller SC, Jee WSS. Ethane-l-hydroxy-1,1-diphosphonate (EHDP) effects on growth and modeling of the rat tibia. CalcTiss Res, 1975; 15:215-31.
53. Miller SC, Jee WSS, Kimmei DB, Woodbury L. Ethane-l-hydroxy-1, 1-diphosphonate (EHDP) effects on incorporation and accumulatino of osteoclast nuclei. Calc Tiss Res 1977; 22: 243-52.
54. Minkin C, Rabadjija L, Goldhaber P. Bone remodelling in vitro: The effects of two disphosphonates on osteoid synthesis and bone resorption in mouse calvaria. Calc Tiss Res 1974; 14: 164-8.
55. Morgan DB, Gasser A, Largiader U, Jung A, Fleisch H. Effect of diphosphonate on calcium metabolism in calcium deprived rats. AmerJ Physiol 1975; 228: 1750-6.
56. Mühlemann HR, Bowles D, Schait A, Bernimoulin ]P, Effect of diphosphonate on human supragingival calculus. Helv OdontActa 1970; 14: 31-3.
57. Nixon GA, Buehler EV, Newman EA. Preliminary safety assessment of disodium etidronate as an additive to experimental oral hygiene products. Toxicol Appl Pharmacol 1972; 22:661-71.
58. Plasmans CMT, Jap PHK, Kuijpers W, Sloof TJJH. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calc Tiss Inti 1980; 32:247-56.
59. Regolati B, Mühlemann HR. Effects of diphosphonate and fluoride on caries, fluorine content and dissolution of rat molars. Helv OdontActa 1970; 14:37-43.
60. Reynolds JJ, Murphy H, Mühlbauer RC, Morgan DB, Fleisch H. Inhibition by diphosphonates on bone resorption in mice and comparison with greylethal osteopetrosis. Calc Tiss Res 1973; 12: 59-71.
61. Rosenblum IY. The effects of disodium ethane-l-hydroxy-1, 1-diphosphonate (EHDP)on mineral and orga-
Pirofosfat ve Bisfosfonatların
Kalsifikasyon Üzerine Etkileri
111
nic
component
s of rat bone, Calc Tiss Res 1974; 16; 239-50.
62. Rowe DJ, Hausmann E. The alteraüon of osteoclast morphology by diphosphonates in bone culture. CalcTiss Res 1976; 20: 53-60.
63. Russell RGG, Bisaz S, Fleisch H, Currey HLF, Rubinstein HM, Dietz AA, Bouissina I, Mİchelİ A, Pallet G. Inorganic pyrophosphate in plasma, urine and synovial fluid of patients with pyrophospate arthropathy (chondrocal-cinosis or pseudogut). Lancet 1970; 2:899-902.
64. Russel RGG, Smith R. Diphosphonates. Experimental and clinical aspects./BoneJoint Surg 1973; B55: 66-86.
65 Sahni M, Guenter HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts./ Clin Invest 1993; 51.2004-11.
66. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Radon GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure./ Clin /nines* 1991; 8& 2095-105.
67. Schibier D, Russell RGG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats, din Sei 1968; 55:363-72.
68. Storm T, Thambsborg G, Steiniche T, Genant HK, Sörensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEnglJMed 1990; 522:1265-71.
69. Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992:13: 249-55.
70. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yano-ver MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH. Intermittent cyclical etidronate treament of postmenopausal osteoporosis. NEnglJ Med 1990: 525:73-9.
71. Weinstein RS. Focal mineralization defect during disodium etidronate treament of calcinosis. Calc Tiss Intl 1982: 5*224-8.

Thank you for copying data from http://www.arastirmax.com